US Stock MarketDetailed Quotes

TAK Takeda Pharmaceutical

Watchlist
  • 13.100
  • +0.090+0.69%
Close Dec 20 16:00 ET
41.68BMarket Cap22.51P/E (TTM)

Takeda Pharmaceutical Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q2)Sep 30, 2024
(Q1)Jun 30, 2024
(FY)Mar 31, 2024
(Q4)Mar 31, 2024
(Q3)Dec 31, 2023
(Q2)Sep 30, 2023
(Q1)Jun 30, 2023
(FY)Mar 31, 2023
(Q4)Mar 31, 2023
(Q3)Dec 31, 2022
Total revenue
12.75%1.18T
14.11%1.21T
5.87%4.26T
9.91%1.05T
1.33%1.11T
4.07%1.04T
8.86%1.06T
12.85%4.03T
9.49%956.16B
21.66%1.1T
Operating revenue
12.75%1.18T
14.11%1.21T
5.87%4.26T
9.91%1.05T
1.33%1.11T
4.07%1.04T
8.86%1.06T
12.85%4.03T
9.49%956.16B
21.66%1.1T
Cost of revenue
14.76%394.31B
20.50%386.95B
14.68%1.43T
23.48%382.5B
12.95%379.48B
12.49%343.58B
9.64%321.11B
12.40%1.24T
0.45%309.77B
19.39%335.97B
Gross profit
11.75%781.73B
11.33%821.04B
1.93%2.84T
3.40%668.37B
-3.80%731.71B
0.38%699.51B
8.52%737.5B
13.05%2.78T
14.42%646.38B
22.70%760.58B
Operating expense
-32.15%508.09B
15.08%654.71B
12.91%2.52T
15.83%571.56B
29.21%792.79B
26.40%748.85B
7.54%568.93B
16.30%2.23T
2.52%493.44B
21.89%613.59B
Selling and administrative expenses
6.06%268.28B
8.83%270.03B
5.67%1.05T
11.95%285.23B
1.99%267.52B
1.70%252.95B
7.19%248.11B
12.52%997.31B
14.04%254.8B
13.51%262.3B
Research and development costs
-4.56%175.56B
3.52%168.46B
15.25%729.92B
21.69%195.86B
7.30%187.38B
19.33%183.95B
13.32%162.74B
20.38%633.33B
12.06%160.94B
36.03%174.63B
Depreciation amortization depletion
-52.28%114.65B
25.81%162.83B
20.22%652.12B
8.92%145.11B
86.68%253.09B
68.75%240.24B
-1.41%129.42B
14.70%542.44B
-10.76%133.22B
14.81%135.58B
-Depreciation and amortization
-52.28%114.65B
25.81%162.83B
20.22%652.12B
8.92%145.11B
86.68%253.09B
68.75%240.24B
-1.41%129.42B
14.70%542.44B
-10.76%133.22B
14.81%135.58B
Other operating expenses
-170.30%-50.41B
86.29%53.38B
44.78%80.27B
1.58%-54.65B
106.40%84.8B
51.99%71.71B
26.22%28.66B
80.28%55.44B
-58.59%-55.53B
58.86%41.08B
Operating profit
654.57%273.64B
-1.33%166.33B
-42.16%320.95B
-36.70%96.81B
-141.56%-61.08B
-147.25%-49.34B
12.00%168.57B
1.62%554.89B
82.99%152.95B
26.19%146.99B
Net non-operating interest income expense
-32.21%-64.34B
12.40%-29.01B
-13.84%-140.46B
73.14%-13.9B
-17.62%-44.78B
-24.71%-48.66B
-707.04%-33.12B
0.07%-123.39B
-126.11%-51.75B
10.55%-38.07B
Non-operating interest income
-56.02%4.12B
15.96%30.68B
105.03%11.29B
29.85%-34.81B
-47.72%21.79B
-36.69%9.36B
-56.58%26.46B
19.97%5.51B
-29.37%-49.62B
905.52%41.68B
Non-operating interest expense
17.98%68.45B
0.19%59.69B
2.19%119.54B
-442.57%-53.13B
-16.53%66.57B
7.84%58.02B
7.40%59.58B
-4.46%116.97B
53.61%-9.79B
70.75%79.75B
Total other finance cost
----
----
170.31%32.22B
----
----
----
----
111.50%11.92B
----
----
Other net income (expense)
-4,540.79%-89.93B
-70.33%-712M
-126.37%-127.7B
-144.81%-130.43B
9,557.89%167.12B
333.03%2.03B
15.90%-418M
52.99%-56.41B
53.57%-53.28B
-2.14%-1.77B
Gain on sale of security
----
----
-241.82%-9.13B
----
----
----
----
126.60%6.44B
----
----
Earnings from equity interest
-126.42%-535M
-70.33%-712M
-53.05%6.47B
-77.88%3.74B
163.61%1.12B
333.03%2.03B
15.90%-418M
300.23%13.79B
1,137.98%16.92B
-2.14%-1.77B
Special income (charges)
----
----
-63.15%-125.04B
----
----
----
----
13.79%-76.64B
----
----
-Less：Restructuring and merger&acquisition
----
----
61.51%102.12B
----
----
----
----
-12.96%63.23B
----
----
-Less:Other special charges
----
----
122.71%18.16B
----
----
----
----
120.50%8.15B
----
----
-Write off
----
----
-10.04%12.74B
----
----
----
----
-31.67%14.16B
----
----
-Gain on sale of business
----
----
15.04%7.83B
----
----
----
----
-2.98%6.81B
----
----
-Gain on sale of property,plant,equipment
----
----
-93.12%144M
----
----
----
----
82.40%2.09B
----
----
Income before tax
224.37%119.37B
1.16%136.6B
-85.93%52.79B
-199.18%-47.52B
-42.83%61.26B
-248.69%-95.98B
-13.15%135.03B
23.97%375.09B
188.65%47.92B
48.43%107.15B
Income tax
156.79%27.27B
-9.47%41.3B
-257.46%-91.41B
-365.38%-44.53B
-270.92%-44.5B
-1,804.26%-48.01B
-9.56%45.63B
-19.82%58.05B
139.32%16.78B
-183.46%-12B
Net income
292.01%92.11B
6.59%95.3B
-54.52%144.2B
-109.62%-2.99B
-11.24%105.76B
-177.71%-47.97B
-14.87%89.41B
37.74%317.04B
373.71%31.14B
106.07%119.15B
Net income continuous Operations
292.00%92.11B
6.59%95.3B
-54.52%144.2B
-109.62%-2.99B
-11.24%105.76B
-177.71%-47.97B
-14.87%89.41B
37.74%317.04B
373.72%31.14B
106.07%119.15B
Minority interest income
3.39%61M
363.64%51M
519.05%130M
1,100.00%24M
59.09%35M
690.00%59M
57.14%11M
-80.37%21M
111.76%2M
-56.86%22M
Net income attributable to the parent company
291.64%92.05B
6.55%95.25B
-54.56%144.07B
-109.69%-3.02B
-11.25%105.72B
-177.79%-48.03B
-14.87%89.4B
37.80%317.02B
374.12%31.13B
106.21%119.13B
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
291.64%92.05B
6.55%95.25B
-54.56%144.07B
-109.69%-3.02B
-11.25%105.72B
-177.79%-48.03B
-14.87%89.4B
37.80%317.02B
374.12%31.13B
106.21%119.13B
Basic earnings per share
289.50%29.07
5.56%30.355
-54.92%46.045
-110.07%-1.005
-11.80%33.795
-177.14%-15.34
-15.35%28.755
38.84%102.145
387.34%9.985
107.61%38.315
Diluted earnings per share
286.34%28.585
4.94%29.97
-54.86%45.58
-110.42%-1.005
-11.84%33.44
-177.71%-15.34
-15.45%28.56
38.44%100.97
369.41%9.645
106.82%37.93
Dividend per share
-2.29%46.5694
0
3.35%91.889
7.08%44.2266
0
0.11%47.6624
0
4.95%88.9091
2.53%41.301
0
Currency Unit
JPY
JPY
JPY
JPY
JPY
JPY
JPY
JPY
JPY
JPY
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
Unqualified Opinion with Explanatory Notes
--
--
--
--
--
--
--
(Q2)Sep 30, 2024(Q1)Jun 30, 2024(FY)Mar 31, 2024(Q4)Mar 31, 2024(Q3)Dec 31, 2023(Q2)Sep 30, 2023(Q1)Jun 30, 2023(FY)Mar 31, 2023(Q4)Mar 31, 2023(Q3)Dec 31, 2022
Total revenue 12.75%1.18T14.11%1.21T5.87%4.26T9.91%1.05T1.33%1.11T4.07%1.04T8.86%1.06T12.85%4.03T9.49%956.16B21.66%1.1T
Operating revenue 12.75%1.18T14.11%1.21T5.87%4.26T9.91%1.05T1.33%1.11T4.07%1.04T8.86%1.06T12.85%4.03T9.49%956.16B21.66%1.1T
Cost of revenue 14.76%394.31B20.50%386.95B14.68%1.43T23.48%382.5B12.95%379.48B12.49%343.58B9.64%321.11B12.40%1.24T0.45%309.77B19.39%335.97B
Gross profit 11.75%781.73B11.33%821.04B1.93%2.84T3.40%668.37B-3.80%731.71B0.38%699.51B8.52%737.5B13.05%2.78T14.42%646.38B22.70%760.58B
Operating expense -32.15%508.09B15.08%654.71B12.91%2.52T15.83%571.56B29.21%792.79B26.40%748.85B7.54%568.93B16.30%2.23T2.52%493.44B21.89%613.59B
Selling and administrative expenses 6.06%268.28B8.83%270.03B5.67%1.05T11.95%285.23B1.99%267.52B1.70%252.95B7.19%248.11B12.52%997.31B14.04%254.8B13.51%262.3B
Research and development costs -4.56%175.56B3.52%168.46B15.25%729.92B21.69%195.86B7.30%187.38B19.33%183.95B13.32%162.74B20.38%633.33B12.06%160.94B36.03%174.63B
Depreciation amortization depletion -52.28%114.65B25.81%162.83B20.22%652.12B8.92%145.11B86.68%253.09B68.75%240.24B-1.41%129.42B14.70%542.44B-10.76%133.22B14.81%135.58B
-Depreciation and amortization -52.28%114.65B25.81%162.83B20.22%652.12B8.92%145.11B86.68%253.09B68.75%240.24B-1.41%129.42B14.70%542.44B-10.76%133.22B14.81%135.58B
Other operating expenses -170.30%-50.41B86.29%53.38B44.78%80.27B1.58%-54.65B106.40%84.8B51.99%71.71B26.22%28.66B80.28%55.44B-58.59%-55.53B58.86%41.08B
Operating profit 654.57%273.64B-1.33%166.33B-42.16%320.95B-36.70%96.81B-141.56%-61.08B-147.25%-49.34B12.00%168.57B1.62%554.89B82.99%152.95B26.19%146.99B
Net non-operating interest income expense -32.21%-64.34B12.40%-29.01B-13.84%-140.46B73.14%-13.9B-17.62%-44.78B-24.71%-48.66B-707.04%-33.12B0.07%-123.39B-126.11%-51.75B10.55%-38.07B
Non-operating interest income -56.02%4.12B15.96%30.68B105.03%11.29B29.85%-34.81B-47.72%21.79B-36.69%9.36B-56.58%26.46B19.97%5.51B-29.37%-49.62B905.52%41.68B
Non-operating interest expense 17.98%68.45B0.19%59.69B2.19%119.54B-442.57%-53.13B-16.53%66.57B7.84%58.02B7.40%59.58B-4.46%116.97B53.61%-9.79B70.75%79.75B
Total other finance cost --------170.31%32.22B----------------111.50%11.92B--------
Other net income (expense) -4,540.79%-89.93B-70.33%-712M-126.37%-127.7B-144.81%-130.43B9,557.89%167.12B333.03%2.03B15.90%-418M52.99%-56.41B53.57%-53.28B-2.14%-1.77B
Gain on sale of security ---------241.82%-9.13B----------------126.60%6.44B--------
Earnings from equity interest -126.42%-535M-70.33%-712M-53.05%6.47B-77.88%3.74B163.61%1.12B333.03%2.03B15.90%-418M300.23%13.79B1,137.98%16.92B-2.14%-1.77B
Special income (charges) ---------63.15%-125.04B----------------13.79%-76.64B--------
-Less：Restructuring and merger&acquisition --------61.51%102.12B-----------------12.96%63.23B--------
-Less:Other special charges --------122.71%18.16B----------------120.50%8.15B--------
-Write off ---------10.04%12.74B-----------------31.67%14.16B--------
-Gain on sale of business --------15.04%7.83B-----------------2.98%6.81B--------
-Gain on sale of property,plant,equipment ---------93.12%144M----------------82.40%2.09B--------
Income before tax 224.37%119.37B1.16%136.6B-85.93%52.79B-199.18%-47.52B-42.83%61.26B-248.69%-95.98B-13.15%135.03B23.97%375.09B188.65%47.92B48.43%107.15B
Income tax 156.79%27.27B-9.47%41.3B-257.46%-91.41B-365.38%-44.53B-270.92%-44.5B-1,804.26%-48.01B-9.56%45.63B-19.82%58.05B139.32%16.78B-183.46%-12B
Net income 292.01%92.11B6.59%95.3B-54.52%144.2B-109.62%-2.99B-11.24%105.76B-177.71%-47.97B-14.87%89.41B37.74%317.04B373.71%31.14B106.07%119.15B
Net income continuous Operations 292.00%92.11B6.59%95.3B-54.52%144.2B-109.62%-2.99B-11.24%105.76B-177.71%-47.97B-14.87%89.41B37.74%317.04B373.72%31.14B106.07%119.15B
Minority interest income 3.39%61M363.64%51M519.05%130M1,100.00%24M59.09%35M690.00%59M57.14%11M-80.37%21M111.76%2M-56.86%22M
Net income attributable to the parent company 291.64%92.05B6.55%95.25B-54.56%144.07B-109.69%-3.02B-11.25%105.72B-177.79%-48.03B-14.87%89.4B37.80%317.02B374.12%31.13B106.21%119.13B
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 291.64%92.05B6.55%95.25B-54.56%144.07B-109.69%-3.02B-11.25%105.72B-177.79%-48.03B-14.87%89.4B37.80%317.02B374.12%31.13B106.21%119.13B
Basic earnings per share 289.50%29.075.56%30.355-54.92%46.045-110.07%-1.005-11.80%33.795-177.14%-15.34-15.35%28.75538.84%102.145387.34%9.985107.61%38.315
Diluted earnings per share 286.34%28.5854.94%29.97-54.86%45.58-110.42%-1.005-11.84%33.44-177.71%-15.34-15.45%28.5638.44%100.97369.41%9.645106.82%37.93
Dividend per share -2.29%46.569403.35%91.8897.08%44.226600.11%47.662404.95%88.90912.53%41.3010
Currency Unit JPYJPYJPYJPYJPYJPYJPYJPYJPYJPY
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ----Unqualified Opinion with Explanatory Notes--------------
Heat List
US
Overall
Symbol
Price
% Chg

No Data

Investment Theme Infectious Disease
Infectious Disease
Intraday+0.78%